Azacitidine

Catalog No.S1782 Synonyms: NSC 102816

Azacitidine  Chemical Structure

Molecular Weight(MW): 244.2

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

4 Customer Reviews

  • R-2HG treatment or chemotherapeutic treatment, especially their combinations, decrease MYC levels in leukemic cells (using MONOMAC-6 as a representative). AZA:Azacitidine.

    Cell, 2018, 172(1-2):90-105. Azacitidine purchased from Selleck.

    Cells were treated with 50 µM AZA and 2 different concentrations of each HDACi for 72 h before cell viability was determined. Data is represented as percent in comparison to vehicle (DMSO) treated cells (set to 100%).

    Epigenetics, 2015, 10(5): 431-45. Azacitidine purchased from Selleck.

  • (A) The graph shows percentage of human CD45+ leukemic cells in mouse blood. At time 0, mice were injected with MV4;11 cells. The arrow indicates when drug treatment began. (B) Kaplan-Meier plot shows the percentage of mice surviving following treatment. The p-value for median survival between different treatment groups (by ANOVA) is<0.0001. The mice treated with the combination of azacitidine and panobinostat were disease-free until they were sacrificed 18 months post cell injection.

    Leuk Res, 2017, 58:91-97. Azacitidine purchased from Selleck.

    Dose response curves for azacitidine from 3-5 independent experiments performed in triplicates were generated using GraphPad Prism software. The calculated IC50s are shown.

    Leuk Res, 2018, 58:91-97. Azacitidine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  M4OyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOwMlEuPTBizszN MVmxNk04OiCq NWe2U451cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHXaem0zPjF|M{K0Oi=>
Jurkat  NUT5NZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiwMlEuPTBizszN M1L4V|EzNTd{IHi= NUL1b5d{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUiyOlE{OzJ2Nh?=
CA46 M2DwT2Z2dmO2aX;uJGF{e2G7 MWSyNOKhyrWP NYW1cYE4PDhiaB?= M4[weolv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?= MWCyOlE{OzJ2Nh?=
Raji  MonJSpVv[3Srb36gRZN{[Xl? MWGxOeKhyrWP NXvBV5JuPDhiaB?= NHPhZ4JqdmO{ZXHz[ZPDqFCWUFyxxsBuWk6DIHX4dJJme3Orb36= NFSwZoQzPjF|M{K0Oi=>
Jurkat  NYHTSotlTnWwY4Tpc44hSXO|YYm= MVezMlXDqML3TR?= Mn\3OFghcA>? NX32ZlF{cW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO|aX;u M4Gw[lI3OTN|MkS2
MDA-MB-231 NFPqeWNHfW6ldHnvckBCe3OjeR?= NUSwco41OS9{LkWvOUDPxE1? M{fPXlQ5KGh? MojU[IVkemWjc3XzJJRp\SCSVGDONVIh\XiycnXzd4lwdiCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhPcLizszNJFQ5yqCq NInkfYkzPThzN{KyPS=>
MDA-MB-231 MoqwSpVv[3Srb36gRZN{[Xl? MUCxM|IvPS93IN88US=> NVSxV49DPDhiaB?= MUPpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCHLXPh[IhmemmwIH3SUmEh[XRidHjlJINwdmOncn70doF1cW:wIH;mJFIvPcLizszN[o9zKDR6wrDo MonNNlU5OTd{Mkm=
MDA-MB-231 NIqxU4lHfW6ldHnvckBCe3OjeR?= MXexM|IvPS93IN88US=> MX[yOE81QCCq NFnVeVFqdmS3Y3XzJEB{cWewaX\pZ4FvfCCSQWLQJINt\WG4YXflJIFnfGW{IES4JIg> Mmi1NlU5OTd{Mkm=
MCF-7 NEnhT4tHfW6ldHnvckBCe3OjeR?= M4fCd|EwOi53L{Wg{txO NF\iZ3czPC92ODDo MUHpcoNz\WG|ZYOgVGFTWCClbHXheoFo\cLi NEfLR|UzPThzN{KyPS=>
MDA-MB-231  NF[wfFhHfW6ldHnvckBCe3OjeR?= M{HTXlEwOi53L{Wg{txO M33GXVI1NzR6IHi= M1nMNolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBucVKQQT2xNlQh[XRidHjlJINwdmOncn70doF1cW:wIH;mJFUh|ryP MX[yOVgyPzJ{OR?=
A498 NWexVGFTTnWwY4Tpc44hSXO|YYm= MVWxNEDDvU1? M3;2VFczKGh? MmfVbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO|aX;u MUiyOVU3QTB6Nh?=
CaKI-2 M{fFSGZ2dmO2aX;uJGF{e2G7 MX2xNEDDvU1? M3r5N|czKGh? M1PjRolv\HWlZYOgeIhmKEGGQV3UV|E5KGenbnWg[ZhxemW|c3nvci=> M{\He|I2PTZ7MEi2
Ketr-3 MknzSpVv[3Srb36gRZN{[Xl? NXnkcmJpOTBiwsXN NEjGN3g4OiCq NH\HTXZqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44> NHXXeW8zPTV4OUC4Oi=>
A253 NYXKcZh4TnWwY4Tpc44hSXO|YYm= NVqwUXQ2OTBiwsXN MoG5NE01KGR? NWnvW5I6cW6lcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WsLiYX\0[ZIhOjRiaB?= NHj6cGkzPTR6NUWzOi=>
A253 NIPyWY1HfW6ldHnvckBCe3OjeR?= Mln4NVAhyrWP MVy3NkBp NHTOcpNqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[geIhmKE1|UjDpckBjd3SqIH3lcYJz[W6nIHHu[EBkgXSxc3;sbYMheHKncHHyZZRqd26| MnHvNlU1QDV3M{[=
A253 M2W0NmZ2dmO2aX;uJGF{e2G7 M4\Tb|ExKML3TR?= NEXmV|YxNTRiZB?= NH7HU4hz\WS3Y3XzJJRp\SB3LX3leIh6dGO7dH;zbY5mKGOxboTlcpQ> M2fxflI2PDh3NUO2
PC3 NWK2fnBLTnWwY4Tpc44hSXO|YYm= Ml3nNE4zKM7:TdMg MmPYOEBl MYLpcoNz\WG|ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCLR1\CVFctKFOIUmCxJIFv\CCVTFO2RVE2KGOxbXLpcoVlKHerdHigS3NMOTJ4 NGe0TnYzPTR5N{O0NC=>
MCF7 NUfsbXR{TnWwY4Tpc44hSXO|YYm= NITWPJMxNjNizszNxsA> MXK0JIQ> M3;rUIlv[3KnYYPld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyxiU1\SVFEh[W6mIGPMR|ZCOTViY3;tZolv\WRid3n0bEBIW0tzMk[= NVP3cGhSOjV2N{ezOFA>
PC3 NXTzcW57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LkR|AvOiEQvF5CpC=> M{S3dFQh\A>? NYDsfoJv\GWlcnXhd4V{KHSqZTDj[YxtKGe{b4f0bEB1dyB{MD6zKUBkd22kaX7l[EB4cXSqIFfTT|EzPg>? MV:yOVQ4PzN2MB?=
MCF7 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXK2OFU5OC5|IN88UeKh MUC0JIQ> MmTm[IVkemWjc3XzJJRp\SClZXzsJIdzd3e2aDCyOE45LSClb33ibY5m\CC5aYToJGdUUzF{Nh?= M4PGR|I2PDd5M{Sw
BGC-823 MXjGeY5kfGmxbjDBd5NigQ>? NGXNRpg2yqEQvF2= M2fmVlczKGh? NGTnW3Bl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6 M1;TV|I2PDd3N{Oz
MKN28 M2njZmZ2dmO2aX;uJGF{e2G7 MmfxOeKh|ryP MknWO|IhcA>? NVnLd4F7\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? MW[yOVQ4PTd|Mx?=
SGC-7901 NFXkboZHfW6ldHnvckBCe3OjeR?= MkHvOeKh|ryP MV:3NkBp MoH3[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=> NGHDe5kzPTR5NUezNy=>
MKN45 NFXhXGVHfW6ldHnvckBCe3OjeR?= NILFOXk2yqEQvF2= MUm3NkBp MWHk[YNz\WG|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5 Mlj1NlU1PzV5M{O=
BGC-823 M2fMWmZ2dmO2aX;uJGF{e2G7 MnT0OeKh|ryP M4fCflczKGh? MXTk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 M2PYTVI2PDd3N{Oz
MKN28 Ml\FSpVv[3Srb36gRZN{[Xl? MXS1xsDPxE1? MVK3NkBp M2nzV4Rm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm= MmW5NlU1PzV5M{O=
SGC-7901 NFP1XoFHfW6ldHnvckBCe3OjeR?= MUS1xsDPxE1? M3LNTVczKGh? NVzXe4VL\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> MWmyOVQ4PTd|Mx?=
MKN45 MnLPSpVv[3Srb36gRZN{[Xl? NE\Bc4k2yqEQvF2= NFPo[Ws4OiCq MoTp[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= Mnv4NlU1PzV5M{O=
HREC NUTqUpd5TnWwY4Tpc44hSXO|YYm= MVu1M|ExyqEQvF2= NETIWJY1QCCq NVW0VW14cW6mdXPld{BRTUSIIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVrtZ4xDOjV|NUK3OFc>
HRPE MYTGeY5kfGmxbjDBd5NigQ>? NIDmfmE2NzFywrFOwG0> NHnzb4E1QCCq MnvEbY5lfWOnczDQSWRHKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mlu2NlU{PTJ5NEe=
HREC MnzzSpVv[3Srb36gRZN{[Xl? NVj5VIFJPS9zMNMg{txO MkLlOFghcA>? NXOy[VR[\G:5bj3y[Yd2dGG2ZYOgc4YhXkWJRjygTWNCVS1zIDjuc5QheHKxdHXpckBt\X[nbDDpckBJWlCHIHPlcIx{MSxiSVytNe6zKGSxc3Wt[IVx\W6mZX70cJk> NF;OVJYzPTN3Mke0Oy=>
HRPE MVTGeY5kfGmxbjDBd5NigQ>? NHq3VYc2NzFywrFOwG0> MWq0PEBp MWfkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLTD2x{tItKGGwZDDNUXAzKGSxc3Wt[IVx\W6mZX70cJk> NF3qN2YzPTN3Mke0Oy=>
MSCs MoW4SpVv[3Srb36gRZN{[Xl? MofQNVAh|ryP NFTXOmUzPCCq M4CwNJBzd22xdHXzJJRp\SClb33tbZRu\W62IH;mJG1US3NidH:gcZlw[2G{ZHnhcEBlcW[oZYLlcpRq[XSrb36= NHvIPGgzPTN3MUO5OS=>
HL-60 NH\rbFFHfW6ldHnvckBCe3OjeR?= M{HRRVUh|ryP Mn7pO|IhcA>? NUTuPVVkTE2VTx?= NELs[WV{cWewaX\pZ4FvfGy7IIXwdoVofWyjdHXzJHpPTjN6MjDlfJBz\XO|aX;u MX:yOVMyQTB2OR?=
MV4-11 MWjGeY5kfGmxbjDBd5NigQ>? M13CWlUh|ryP NIHYXnE4OiCq MYnEUXNQ MkTZd4lodmmoaXPhcpRtgSC3cILl[5Vt[XSnczDaUmY{QDJiZYjwdoV{e2mxbh?= MUGyOVMyQTB2OR?=
A2780 MVzGeY5kfGmxbjDBd5NigQ>? MU[1JOK2VcLi Mn7nO{Bl NVjUVlBIcW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?= M2XMdVI2Ojl7Nkm0
CP70 Mk\QSpVv[3Srb36gRZN{[Xl? MoXKOUDDvU4EoB?= MlLnO{Bl NV\WN3RtcW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?= Ml3JNlUzQTl4OUS=
A2780 M3LUT2Z2dmO2aX;uJGF{e2G7 NUjOemRqPSEEtV5CpC=> NGLyVoM4KGR? Mnqwe4Vic2WwczD0bIUhdGW4ZXygc4YhdWW2aInsZZRqd25? MofWNlUzQTl4OUS=
CP70 MlLTSpVv[3Srb36gRZN{[Xl? MmLxOUDDvU4EoB?= M4\zT|ch\A>? NVLZOWJpf2Wja3Xud{B1cGVibHX2[Ywhd2ZibXX0bJlt[XSrb36= MXiyOVI6QTZ7NB?=
OCM3 M2\US2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUewMlUwOS9{IN88US=> MmL4O{Bl M1zFeWROW09? M3;rUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGTldWgzPTF2Nkm4NS=>
92.1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;zNE42NzFxMjFOwG0> NH2yVGc4KGR? MULEUXNQ NFW4XWtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2DPdVI2OTR4OUix
OCM1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInzTWIxNjVxMT:yJO69VQ>? MmTaO{Bl NVPu[|c5TE2VTx?= MV;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M2\4PFI2OTR4OUix
OMM1 NX2ySpJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rUb|AvPS9zL{Kg{txO MlXjO{Bl MYXEUXNQ MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MXKyOVE1Pjl6MR?=
Mel 285 NIDK[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qwe|AvPS9zL{Kg{txO MYK3JIQ> NGDP[3JFVVOR M1nJXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NHX0b5EzPTF2Nkm4NS=>
Mel 290 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYewMlUwOS9{IN88US=> NHHjV|k4KGR? M{fCb2ROW09? MnnKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MmjuNlUyPDZ7OEG=
OCM3 MUTGeY5kfGmxbjDBd5NigQ>? MnnRNE42NzFizszN NH:xPFQ1QCCq M3X3NWROW09? Mljv[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? NEPCcG0zPTF2Nkm4NS=>
92.1 NUTxTZh3TnWwY4Tpc44hSXO|YYm= M2fqW|AvPS9zIN88US=> NX3zTnpkPDhiaB?= MV3EUXNQ Mkfj[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? M1HOZVI2OTR4OUix
OCM1 M3;OO2Z2dmO2aX;uJGF{e2G7 NE[5VIExNjVxMTFOwG0> Mm[4OFghcA>? NYfMc5V[TE2VTx?= Mnrs[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MVOyOVE1Pjl6MR?=
OMM1 Mn3mSpVv[3Srb36gRZN{[Xl? NVzIWGNyOC53L{Gg{txO NFrmTFQ1QCCq NUeyT|RSTE2VTx?= NGfMXmVl\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7 NV\iSmF1OjVzNE[5PFE>
Mel 285 NInMXWJHfW6ldHnvckBCe3OjeR?= NGnYXXoxNjVxMTFOwG0> MX:0PEBp NIDue49FVVOR MkjM[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MmLqNlUyPDZ7OEG=
Mel 290 MkTQSpVv[3Srb36gRZN{[Xl? MWWwMlUwOSEQvF2= NWjQOpVlPDhiaB?= MnvKSG1UVw>? MnX3[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? M2PHUFI2OTR4OUix
OCM3 MWXGeY5kfGmxbjDBd5NigQ>? MmPwNE42NzFizszN NX3MdmxiPDhiaB?= MYXEUXNQ NY\DVnNn\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>? NIf3UWczPTF2Nkm4NS=>
Mel 290 NVvvV|cxTnWwY4Tpc44hSXO|YYm= MWiwMlUwOSEQvF2= NGGxS2E1QCCq M2nnemROW09? NUnJb4lW\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>? MVeyOVE1Pjl6MR?=
OMM1 MWfGeY5kfGmxbjDBd5NigQ>? M2XtNFAvPS9zIN88US=> M2n2NFQ5KGh? Mk\VSG1UVw>? M{e5eIRm[3KnYYPld{Bqdn[jc3nvckBld3OnIHTldIVv\GWwdHz5xsA> NVnicGRROjVzNE[5PFE>
OCM1 NXnBfZNqS2WubDDWbYFjcWyrdImgRZN{[Xl? MXewMlUwOSEQvF2= NWK0NZViPSCm MljtSG1UVw>? MojO[IVkemWjc3XzJJJi\GmjdHnvck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHnubIljcXSrb36= MX2yOVE1Pjl6MR?=
92.1 MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXywMlUwOSEQvF2= NGPDeWI2KGR? NF;n[FVFVVOR NYHi[FB2\GWlcnXhd4V{KHKjZHnheIlwdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIlvcGmkaYTpc44> NF6zdowzPTF2Nkm4NS=>
OCM1 MXnGeY5kfGmxbjDBd5NigQ>? MUGwMlUwOSEQvF2= M13qPVQ5KGh? MV3EUXNQ M3TCZ4NifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m= M3fVXlI2OTR4OUix
OCM3 NYXpSnFCTnWwY4Tpc44hSXO|YYm= NXS5[WNjOC53L{Gg{txO Mkf0OFghcA>? NWDRcldmTE2VTx?= NV;KfoRw[2G3c3XzJIdtd2KjbDDEUmEhcHmyb33leIh6dGG2aX;uJIF1KExvMTDy[ZBm[XRibH;jbS=> MmnYNlUyPDZ7OEG=
92.1 NYPIUYM6TnWwY4Tpc44hSXO|YYm= MWqwMlUwOSEQvF2= M2i0S|Q5KGh? NInMW3JFVVOR M3vxUoNifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m= MVqyOVE1Pjl6MR?=
IMR32 M{HvdGZ2dmO2aX;uJGF{e2G7 MUSzJO69VQ>? NIPBc2U4OiCq NIPaR4FFVVOR Mny1bY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC|aXfubYZq[2GwdHz5 MmLUNlUyODR6NUC=
IMR5-75 MUfGeY5kfGmxbjDBd5NigQ>? MnnBN{DPxE1? Mmj6O|IhcA>? NFf0VXFFVVOR Ml:5bY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC|aXfubYZq[2GwdHz5 M3vKS|I2OTB2OEWw
Be(2)-C M1;He2Z2dmO2aX;uJGF{e2G7 NFnRNHE{KM7:TR?= MXe3NkBp MWDEUXNQ NFvjOZRqdmS3Y3XzxsBxOTlvSV7LOITDqGW6cILld5Nqd28EoIPp[45q\mmlYX70cJk> M17zNlI2OTB2OEWw
Bxpc-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG1M|ExKM7:TR?= MUKyOE81QC95MjDo NF25SJFqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCEeIDjMVMh[2WubIOgbY4hfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6ncoO= Mkf5NlUxPjF5M{G=
Bxpc-3 NEPJdoRCeG:ydH;zbZMhSXO|YYm= Mn2zOU8yOCEQvF2= MlHINlQwPDhxN{KgbC=> MX7pcoR2[2W|IHHwc5B1d3OrczDpckB1cW2nLTDhcoQh[2:wY3XycpRz[XSrb36gcYFvdmW{cx?= MnnqNlUxPjF5M{G=
Bxpc-3 M3LJOmZ2dmO2aX;uJGF{e2G7 M2LZUVUwOTBizszN Mnr5NlQwPDhxN{KgbC=> NV\UbnZF\GWlcnXhd4V{KM7{LXPheIVvcW5iZYjwdoV{e2mxbjDh[pRmeiB{NDDo M2fwN|I2ODZzN{Ox
Bxpc-3 M3\BXmZ2dmO2aX;uJGF{e2G7 NEK2fFk2NzFyIN88US=> M1XQRlI1NzR6L{eyJIg> NGH4fotl\WO{ZXHz[ZMh[3mlbHnuSFEh\XiycnXzd4lwdiCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhOTBizszN MUOyOVA3OTd|MR?=
Bxpc-3 MYfGeY5kfGmxbjDBd5NigQ>? NYfNXYVyPS9zMDFOwG0> MnrRNlQwPDhxN{KgbC=> NH65UmVld3ewLYLl[5Vt[XSnUzDjMY16[yCvUl7BJIV5eHKnc4Ppc44hcW5idHnt[U0h[W6mIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldpM> MWCyOVA3OTd|MR?=
HL-60 NWrORWtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfvVVYyNjBizszN NXTjXGpyPDhiaB?= NHLJZVB{cWewaX\pZ4FvfGy7IHnubIljcXS|IFjMMVYxKGOnbHyg[5Jwf3SqwrC= MmPlNlUxPTFzMUm=
HL-60 NGrwd2JHfW6ldHnvckBCe3OjeR?= MXOxMlAh|ryP MYW0PEBp MYfpcoNz\WG|ZYOgdFIyX0GIMT;DTXAyyqCjbnSgZ4F{eGG|ZT2zJIV5eHKnc4Ppc47DqA>? NFL4OoMzPTB3MUGxPS=>
HL-60 MVjGeY5kfGmxbjDBd5NigQ>? MVyxMlAh|ryP MWC0PEBp NUHiN3VI\GWlcnXhd4V{KEKlbD34UEBmgHC{ZYPzbY9vyqC|aXfubYZq[2GwdHz5 MlmxNlUxPTFzMUm=
HuTu-80  MWHGeY5kfGmxbjDBd5NigQ>? NGnaUmoyNzVxMUCg{txO M{noTVQ5Nzd{IHi= NF[wOXpqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhcHWvYX6gUnBEOUxzIH3SUmEhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NULZepdLOjR7MESwOlI>
Caco2  NX\EflM5TnWwY4Tpc44hSXO|YYm= MUexNEDPxE1? MXO0PEBp NFHOdJpqdmO{ZXHz[ZMhVlCFMVyxJIV5eHKnc4Ppc44> MVeyOFkxPDB4Mh?=
HepG2  MoLySpVv[3Srb36gRZN{[Xl? M{fJO|AuOjVizszN MUKyOEBp NFjNWnhl\WO{ZXHz[ZMhe3WkdHnsbZNqdi:tZYjpckB1gXCnIEmgLHBEW0t7KTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6 Mnv0NlQ5PTV4NE[=
HepG2  MoqzSpVv[3Srb36gRZN{[Xl? M33QUVAuOjVizszN M4X3b|I1KGh? M3XpTolv[3KnYYPld{Btd3diZHXud4l1gSCuaYDvdJJwfGWrbjDy[YNmeHSxcjCoUGRNWiliZ3Xu[UBmgHC{ZYPzbY9vyqB? M33JNFI1QDV3NkS2
HepG2  M3nMN2Z2dmO2aX;uJGF{e2G7 M{PpV|ExKM7:bdMg MoPHNE0zPCCq NGDFN3hl\WO{ZXHz[ZPDqFCFU1u5xsBidmUEoFjNS2NTyqCneIDy[ZN{cW:wIHHu[EBqdmO{ZXHz[ZMhVESOUjDlfJBz\XO|aX;uJIFnfGW{IE[gbC=> MX:yOFg2PTZ2Nh?=
HepG2  Ml7QSpVv[3Srb36gRZN{[Xl? MWOxNEDPxG1? NXr5NlRkOjRiaB?= MoPMdJJwdW:2ZYOgZ5l1d3OxbHnjJI5mfXS{YXygcIlxcWRiYXPjeY12dGG2aX;uJIlv\GWyZX7k[Y51dHlib3[g[Zhw\2Wwb4XzJIxqeG:ycn;0[Ylvew>? M4ToSFI1QDV3NkS2
HepG2  NI\ZcGlHfW6ldHnvckBCe3OjeR?= M3zPTlExKM7:bR?= NFTIbmczPCCq MWDwdoV3\W62czDTVmVDWCCycn;j[ZN{cW6p MmfBNlQ5PTV4NE[=
HC45  NHqzUpdHfW6ldHnvckBCe3OjeR?= NGe5WVI2yrWPwrC= NVPzSVJGPCCm MXPy[YR2[2W|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>? NUD1NXlIOjR5NkK4NFk>
CNDT2  M3L0TWZ2dmO2aX;uJGF{e2G7 NEfzbY02yrWPwrC= NVPobpROPCCm Ml7NdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF? NH;ZTVczPDd4MkiwPS=>
CNDT2  M{XVWGZ2dmO2aX;uJGF{e2G7 MVO1xtVOyqB? Mn3jOEBl MVPpcoNz\WG|ZYOg[4Vv\SCneIDy[ZN{cW:wIH;mxsBYUUZzLDDQNVYtKEOGSEGsxsBNSU2DMT|CpIFv\MLiQ2TOUmIy MXeyOFc3OjhyOR?=
T-cells NEXrTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3raeVUwOjBizszN Mmn0NE01QCCq M1HwdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NWfMPHZWOjR5NUeyPFM>
CD3+ T-cells MVTGeY5kfGmxbjDBd5NigQ>? NH\0e3E2NzJyIN88US=> NUOzPWdyPDhiaB?= MnS4eZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36= MWiyOFc2PzJ6Mx?=
CD4+ T-cells M{XCcWZ2dmO2aX;uJGF{e2G7 MmDwOU8zOCEQvF2= NVzFc5ppPDhiaB?= NXq3OmFlfXC{ZXf1cIF1\XNicEG1JIV5eHKnc4Ppc44> M{jwZ|I1PzV5Mkiz
CD8+ T-cells NX30XGlLTnWwY4Tpc44hSXO|YYm= M2[5VVUwOjBizszN Mlj0OFghcA>? M3exUZVxemWpdXzheIV{KHBzNTDlfJBz\XO|aX;u MYmyOFc2PzJ6Mx?=
CD3+ T-cells M{TqXGZ2dmO2aX;uJGF{e2G7 M3nBNlUwOjBizszN NWLNU4VkPDhiaB?= NUXTfGpkfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiRl;YVFM> Mlj5NlQ4PTd{OEO=
CD4+ T-cells NHi3VYpHfW6ldHnvckBCe3OjeR?= M2nQRVUwOjBizszN NF;3[Ws1QCCq MWT1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBHV1iSMx?= NYHTXIFXOjR5NUeyPFM>
CD4+ T-cells NEPuc|ZHfW6ldHnvckBCe3OjeR?= M1HDUlUwOjBizszN NUP4SIdRPDhiaB?= NYSyOJUxemWmdXPld{BVSkWWMdMgcXJPSSCneIDy[ZN{cW:w MlXaNlQ4PTd{OEO=
CD4+ T-cells M1PN[GZ2dmO2aX;uJGF{e2G7 NHH5WGQ2NzJyIN88US=> NV32ZZFWPDhiaB?= MYf1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[uKhWk:UzsP0xsA> MofWNlQ4PTd{OEO=
CD4+ T-cells MWLGeY5kfGmxbjDBd5NigQ>? M17ZbVUwOjBizszN NUTkbmJOPDhiaB?= MoLObY5pcWKrdIOgcYVud3K7IGStZ4VtdHN? M1zJZlI1PzV5Mkiz
CD8+ T-cells NWrjb29RTnWwY4Tpc44hSXO|YYm= MWm1M|IxKM7:TR?= M1nBdVQ5KGh? MYXpcohq[mm2czDt[Y1wenliVD3j[Yxtew>? MUGyOFc2PzJ6Mx?=
CD3+ T-cells NFTtSGZHfW6ldHnvckBCe3OjeR?= NXXDRZlEPSEQvF2= MY[0PEBp NWL6NHlTemWmdXPld{Btd26pLYTldo0hdWWvb4L5JINmdGxicHjlco91gXCn NFjOPG0zPDd3N{K4Ny=>
U937 NFPZ[2xCeG:ydH;zbZMhSXO|YYm= M4njdFExKM7:TR?= NHHNZZQ4OiCq NYS3SVR[cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= MkXHNlQ3QDB6NkW=
HL-60 NUXIZpdtSXCxcITvd4l{KEG|c3H5 NIfKUJMyOCEQvF2= M2C0UlczKGh? MVfpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NGTVUJIzPDZ6MEi2OS=>
MCF7 Mo\2SpVv[3Srb36gRZN{[Xl? MkWwOUDPxE1? M3S4blQ5KGkEoB?= MXLkbZNxdGG7czDz[Yxm[3SrdnWgeI95cWOrdImgeI94[XKmIIP1d5BmdmSnZDDNR2YuPyClZXzsdy=> M{j4S|I1PjN|M{Ww
MCF7 M4DyZWZ2dmO2aX;uJGF{e2G7 NEf6Z|UyOCEQvF2= M2fGflI1KGkEoB?= NUPYeZZucW6mdXPld{B1cGViY3zlZZZi\2Vib3[gZ4F{eGG|ZTC3JIFv\CCSQWLQxsA> MnXYNlQ3OzN|NUC=
MCF7 MUHGeY5kfGmxbjDBd5NigQ>? Mo\vNQKBmzBwNTFOwG3DqA>? NGT6S2Q4KGR? NV;wfJdFcW6qaXLpeJMhfGinIHfyc5d1cCCPQ1[tO{B1fW2xcoPwbIVz\XNiaX6gd5V{eGWwc3nvckBkfWy2dYLld:Kh MXSyOFY{OzN3MB?=
MCF7 NUOyS3ZxTnWwY4Tpc44hSXO|YYm= M{PS[VAvPSEQvF5CpC=> M1Hhc|E1KGR? NHP2Topz\WS3Y3XzJJRp\SC|aYrlJI9nKE2FRj23JINwdG:waXXzJIVu[mWmZHXkJIlvKHOxZoSgZYdieg>? MmKzNlQ3OzN|NUC=
MCF7 MWDGeY5kfGmxbjDBd5NigQ>? MYOwMlA26oDVMkCg{txO MlLUNUBl MmX0doVlfWOnczD0bIUh[2yxbnHsJJN2en[rdnHsJI9nKE2FRj23JINmdGy|IHnuJI1wdm:uYYnldkBkfWy2dYLldy=> NUe5U2hOOjR4M{OzOVA>
T47D  NYC4UXZ2TnWwY4Tpc44hSXO|YYm= Ml\DNE42KM7:TR?= MlziOEBl NHnZXnpqdmirYnn0d{B1fW2xcoPwbIVz\SCob4LtZZRqd25? M{P5[VI1PjN|M{Ww
MCF7 MmrjSpVv[3Srb36gRZN{[Xl? M3PXVVAvPeLCk{GwJO69VQ>? MYG0PEBpyqB? MlTLbY5pcWKrdIOgeIhmKGejcDDjcI9{fXKnIHnuJJRp\SC5b4Xu[EBp\WGuaX7nJIF{e2G7 MUCyOFY{OzN3MB?=
MCF7 MX7GeY5kfGmxbjDBd5NigQ>? NHmyNlMxNzFyIN88US=> NET1PHczPCCq M2rpdYlvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXA6 NHHiVHMzPDZ|M{O1NC=>
MDA-MB-231  M1vqWGZ2dmO2aX;uJGF{e2G7 NVu2T4tsOC534pETNVAh|ryP NFzZbXo{PiCq NVj2TYR[cW6qaXLpeJMhfGinIH3p[5JifGmxbh?= NVT6fo1mOjR4M{OzOVA>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 ; 

PubMed: 28210112     


AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control.

c-PARP / p-H2AX / H2AX; 

PubMed: 28210112     


AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘

28210112
Immunofluorescence
HMGB1 ; 

PubMed: 29097772     


U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemセ᎒

29097772
Growth inhibition assay
Cell viability ; 

PubMed: 28210112     


AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖

28210112
In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
+ Expand
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Formulation: Dissolved in 0.85% NaC1 solution immediately prior to use
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5

CAS No. 320-67-2
Storage powder
in solvent
Synonyms NSC 102816

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03486353 Withdrawn Myelodysplastic Syndrome (MDS) Fujifilm Pharmaceuticals U.S.A. Inc. October 2019 Phase 2
NCT03486353 Withdrawn Myelodysplastic Syndrome (MDS) Fujifilm Pharmaceuticals U.S.A. Inc. October 2019 Phase 2
NCT03850418 Not yet recruiting Myeloid Malignancy Henry Ford Health System June 1 2019 Phase 2
NCT03850418 Not yet recruiting Myeloid Malignancy Henry Ford Health System June 1 2019 Phase 2
NCT03862157 Not yet recruiting Acute Myeloid Leukemia|Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative|Chronic Eosinophilic Leukemia Not Otherwise Specified|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Dysplasia|Essential Thrombocythemia|FGFR1 Gene Rearrangement|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm Unclassifiable|Myeloid Neoplasm|Myeloproliferative Neoplasm|Myeloproliferative Neoplasm Unclassifiable|Overt Primary Myelofibrosis|PDGFRA Gene Rearrangement|PDGFRB Gene Rearrangement|Polycythemia Vera|Polycythemia Vera Post-Polycythemic Myelofibrosis Phase|Prefibrotic/Early Primary Myelofibrosis M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 31 2019 Phase 1|Phase 2
NCT03628209 Not yet recruiting Osteosarcoma|Osteosarcoma in Children|Osteosarcoma Recurrent|Sarcoma H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb May 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

DNA Methyltransferase Signaling Pathway Map

Tags: buy Azacitidine | Azacitidine supplier | purchase Azacitidine | Azacitidine cost | Azacitidine manufacturer | order Azacitidine | Azacitidine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID